

STENOCARE A/S

NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER: STENO

STENOCARE share analyst's comments on the CannGros acquisition

STENOCARE A/S announced November 18 that it had acquired 100% of the shares in CannGros ApS. This press release share additional insight on the value of the acquisition.

Stenocare has paid investor relations agreement with Swedish Analyst Group and Danish Proinvestor.com. With this, Stenocare is offering shareholders and investors the opportunity to have deeper insight into the strategy, the execution and the value for the Company.

Analyst Group is a research firm focused on small- and micro-cap companies. They offer in-depth knowledge in analyzing and providing equity research and helping to increase understanding and transparency of the companies.

- Analyst Group comments on the CannGros acquisition: <https://analystgroup.se/kommentarer/comment-on-stenocares-acquisition-of-canngros-aps/>

Proinvestor.com is the largest independent investor site in Denmark for debate, blogs and news regarding companies and investments. The Editor, Helge Larsen, is their well-known front-person that is a passionate spokesperson for trading on the stock market.

- Proinvestor interview with Stenocare leadership members (with English subtitles): <https://www.linkedin.com/feed/update/urn:li:activity:7396950790998818816>

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

Phone: +45 31770060

E-mail: presse@stenocare.com

About STENOCARE A/S

STENOCARE A/S, founded in 2017, supplies prescription-based medical cannabis to patients in Denmark and internationally. It was the first company to receive permission from the Danish Medicines Agency to import, distribute, cultivate, and produce medical cannabis. Today, STENOCARE sources its products from a selection of high-quality international suppliers that comply with the strict European Good Manufacturing Practices (EU-GMP). STENOCARE has developed a unique patented medical cannabis oil product, ASTRUM, which provides improved bioavailability of active ingredients for patients. The company has strategically invested in assets to operate within the highly regulated pharmaceutical industry, with products approved for sale in multiple countries.

www.stenocare.com www.stenocare.dk